The FDA enforcement report lists Class II recalls of compounded incretin injectables. They include tirzepatide/cyanocobalamin and semaglutide/cyanocobalamin syringes from Carolina Infusion, and a multi-dose tirzepatide vial from Apothecary Pharma. The stated reason is lack of assurance of sterility, linked in the Carolina Infusion entries to the formulation's use of bacteriostatic water and to processing equipment. Both recalls are listed as ongoing.
A Class II recall means use could cause temporary or medically reversible harm, or that serious harm is remote. These are compounded products, not the licensed branded medicines, and the recall does not concern the drugs themselves.
The products are US-compounded and are not expected in Indian supply chains. The lesson travels further: patients increasingly buy incretin injections from compounders, online sellers and unregulated sources, where sterility and dose are not assured.
- Ask patients on an incretin injection where it comes from, and whether it is a licensed product.
- Combination vials adding vitamin B12 to tirzepatide or semaglutide are compounded, not licensed products.
- Ask about injection-site redness, swelling or fever in anyone using a compounded or online-bought injection.
- Report suspected contaminated product reactions to the national pharmacovigilance programme.
Why it matters
Demand for weight-loss injections has created a parallel supply whose quality nobody in the clinic can see.
Don't overread it
A Class II sterility recall is a manufacturing-assurance action, not evidence that patients were harmed or that the licensed drugs are unsafe.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for diabetes & endocrinology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free